Price reductions are only meaningful if the medication is covered for the patients indication under their Medicare Part D plan
and an exit plan defined before entry
6 with a statement from The Partnership for Safe Medicines.
is contracted via the University of Liverpool (no personal payment) to undertake consultancy for Altimmune, AstraZeneca, Boehringer Ingelheim, Cytoki, Eli Lilly, Napp, Novo Nordisk, Menarini, Pfizer, Rhythm Pharmaceuticals, Sanofi, Saniona, Tern, Shionogi and Ysopia and declares personal honoraria/lecture fees from AstraZeneca, Boehringer Ingelheim, Medscape, Menarini, Napp, Novo Nordisk and Rhythm
Branded tirzepatide showed similar early response patterns with stronger results at 12 and 18 months in trial settings
however, several challenges still remain, especially the higher cost of a combined therapy and the worldwide underuse of either GLP-1RAs or SGLT2is in clinical practice, even in patients at high cardiorenal risk